Value
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 6.5 |
| P/S | 9.8 |
| EV/EBITDA | 6.6 |
| Fwd P/E | 9.7 |
| PEG | 10.0 |
| Analyst target | 4.0 |
- ▸Forward P/E: 7.4x
- ▸PEG: 0.05
- ▸Attractively valued
CNMD · Why this verdict
Why CONMED (CNMD) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.5/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
CNMD has strung together four consecutive earnings beats averaging approximately 5.5% positive surprise, and free cash flow runs at 229% of net income — strong operational quality signals — but a confirmed price downtrend with the 200-day moving average slope declining at -5.5% over 30 days, a put/call ratio of 6.00, and less than 1% headroom to the analyst target make this a high-quality business in an unfavorable technical and positioning setup.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company has beaten earnings estimates in each of the last four quarters, with the average positive surprise running near 5.5%, suggesting management has a consistent track record of delivering above market expectations. Earnings | The beat streak extends to six consecutive quarters, maintaining an average positive surprise above 3%. | →Stable |
| CounterWith revenue declining 1% year-over-year, the beats may be driven by cost containment rather than durable revenue growth — a harder lever to pull if further expense reduction becomes difficult. | ||
Free cash flow is 229% of net income and the Piotroski F-Score stands at 7 out of 9, reflecting strong operating cash generation that significantly exceeds reported net income — a sign that earnings are backed by real cash. Quality breakdown | Free cash flow to net income ratio remains above 150% for four consecutive quarters, confirming the cash conversion is structural rather than timing-driven. | →Stable |
| CounterA revenue decline of 1% sustained over multiple periods would eventually compress absolute cash generation even if conversion efficiency holds, narrowing the quality cushion. | ||
The stock is below the 200-day moving average with the slope declining at -5.5% over 30 days and on-balance volume falling, confirming a sustained downtrend that blocks near-term entry regardless of fundamental quality. Momentum breakdown | Price closes above the 200-day moving average for 20 consecutive trading days and on-balance volume reverses to rising, signaling the downtrend has ended. | →Stable |
| CounterDowntrends in small-cap medical devices can reverse sharply on a single positive catalyst; the unbroken earnings beat streak suggests the business is performing well and the stock could recover quickly if sentiment shifts. | ||
A put/call ratio of 6.00 — a highly elevated level — and implied volatility at 126% indicate that options market participants are aggressively hedging or positioning against the stock, a near-term headwind that amplifies downside risk if negative news emerges. Risk breakdown | Put/call ratio falls below 2.0 for four consecutive weeks, indicating a meaningful unwinding of bearish options positioning. | →Stable |
| CounterAn extreme put/call skew can mark a sentiment extreme and historically has, in some instances, preceded short-covering rallies when the feared catalyst fails to materialize. | ||
The company has beaten earnings estimates in each of the last four quarters, with the average positive surprise running near 5.5%, suggesting management has a consistent track record of delivering above market expectations.
→StableEarnings
- Expectation
- The beat streak extends to six consecutive quarters, maintaining an average positive surprise above 3%.
CounterWith revenue declining 1% year-over-year, the beats may be driven by cost containment rather than durable revenue growth — a harder lever to pull if further expense reduction becomes difficult.
Free cash flow is 229% of net income and the Piotroski F-Score stands at 7 out of 9, reflecting strong operating cash generation that significantly exceeds reported net income — a sign that earnings are backed by real cash.
→StableQuality breakdown
- Expectation
- Free cash flow to net income ratio remains above 150% for four consecutive quarters, confirming the cash conversion is structural rather than timing-driven.
CounterA revenue decline of 1% sustained over multiple periods would eventually compress absolute cash generation even if conversion efficiency holds, narrowing the quality cushion.
The stock is below the 200-day moving average with the slope declining at -5.5% over 30 days and on-balance volume falling, confirming a sustained downtrend that blocks near-term entry regardless of fundamental quality.
→StableMomentum breakdown
- Expectation
- Price closes above the 200-day moving average for 20 consecutive trading days and on-balance volume reverses to rising, signaling the downtrend has ended.
CounterDowntrends in small-cap medical devices can reverse sharply on a single positive catalyst; the unbroken earnings beat streak suggests the business is performing well and the stock could recover quickly if sentiment shifts.
A put/call ratio of 6.00 — a highly elevated level — and implied volatility at 126% indicate that options market participants are aggressively hedging or positioning against the stock, a near-term headwind that amplifies downside risk if negative news emerges.
→StableRisk breakdown
- Expectation
- Put/call ratio falls below 2.0 for four consecutive weeks, indicating a meaningful unwinding of bearish options positioning.
CounterAn extreme put/call skew can mark a sentiment extreme and historically has, in some instances, preceded short-covering rallies when the feared catalyst fails to materialize.
Per-dimension breakdown
Quality
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 1.8 |
| ROA | 2.6 |
| Gross margin | 6.9 |
| Op margin | 4.2 |
| Net margin | 2.0 |
| Current ratio | 7.9 |
| FCF quality | 10.0 |
| Moat | 4.6 |
| Piotroski F | 7.8 |
- ▸Excellent cash conversion: 236% FCF/NI
- ▸No competitive moat
- ▸Strong Piotroski F-Score: 7/9
Growth
6.1/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 2.2 |
| EPS growth | 10.0 |
- ▸Declining revenue: -1%
Momentum
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 9.0 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -6.2%/30d — confirmed downtrend
Sentiment
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 6.6 |
| erm sentiment | 5.0 |
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
3.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.3 |
| quality rank | 3.8 |
| growth rank | 0.8 |
Technical
2.6/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.8 |
| support resistance | 3.0 |
| 52w position | 1.9 |
Risk (lower is worse)
4.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 5.4 |
| days to cover | 5.6 |
| volatility | 1.2 |
| put call | 3.1 |
| implied vol | 3.2 |
| max pain risk | 3.0 |
| beta | 7.5 |
| debt equity | 5.9 |
- ▸Elevated put/call: 1.53
- ▸High IV: 61%
- ▸Above max pain $30
Catalyst
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 3.5 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 5.2 |
| dividend safety | 7.0 |
- ▸Perfect beat streak: 4Q
- ▸Dividend: 226.0%
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:5.5>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:41d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.3=NEGATIVE
Warning (1)
- DEATH_CROSS:momentum=5.5>=5.0 recovering
Reward-to-Risk
-0.29
Upside
-3.4%
Downside
11.9%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 52
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $1.1B<$5B
Investment implication
The F-path SELL output reflects an overall score of 5.5 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Value at 7.8) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.3=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.29 — supplementary context, not the trigger for this path.
The strongest dimensions are Value at 7.8, Growth at 6.1, and Catalyst at 6.1; the weakest are Technical at 2.6, Peer rank at 3.2, and Risk (lower is worse) at 4.4. The V9 engine flagged 1 failed gate with 1 warning, producing an asymmetric reward-to-risk of -0.29 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company has beaten earnings estimates in each of the last four quarters, with the average positive surprise running near 5.5%, suggesting management has a consistent track record of delivering above market expectations.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters.
- P2Free cash flow is 229% of net income and the Piotroski F-Score stands at 7 out of 9, reflecting strong operating cash generation that significantly exceeds reported net income — a sign that earnings are backed by real cash.
Trip ifFree cash flow to net income ratio falls below 100% for 2 consecutive quarters.
- P3The stock is below the 200-day moving average with the slope declining at -5.5% over 30 days and on-balance volume falling, confirming a sustained downtrend that blocks near-term entry regardless of fundamental quality.
Trip ifPrice closes above the 200-day moving average for 20 consecutive trading days.
- P4A put/call ratio of 6.00 — a highly elevated level — and implied volatility at 126% indicate that options market participants are aggressively hedging or positioning against the stock, a near-term headwind that amplifies downside risk if negative news emerges.
Trip ifPut/call ratio falls below 2.0 for 4 consecutive weeks.